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Abstract Natural Eggshell Membrane (NEM®) is a new
novel dietary supplement that contains naturally occurring
glycosaminoglycans and proteins essential for maintaining
healthy articular cartilage and the surrounding synovium. The
randomized, multicenter, double-blind, placebo-controlled
Osteoarthritis Pain Treatment Incorporating NEM® clinical
study was conducted to evaluate the efficacy and safety of
NEM® as a treatment for pain and stiffness associated with
osteoarthritis of the knee. Sixty-seven patients were randomly
assigned to receive either oral NEM® 500 mg (n=34) or
placebo (n=33) daily for 8 weeks. The primary endpoint was
the change in overall Western Ontario and McMasters
Universities (WOMAC) Osteoarthritis Index as well as pain,
stiffness, and function WOMAC subscales measured at 10,
30, and 60 days. The clinical assessment was performed on
the intent-to-treat population. Supplementation with NEM®
produced an absolute rate of response that was statistically
significant (up to 26.6%) versus placebo at all time points for
both pain and stiffness, but was not significantly improved
for function and overall WOMAC scores, although trending
toward improvement. Rapid responses were seen for mean
pain subscores (15.9% reduction, P=0.036) and mean stiff-
ness subscores (12.8% reduction, P=0.024) occurring after
only 10 days of supplementation. There were no serious
adverse events reported during the study and the treatment
was reported to be well tolerated by study participants.
Natural Eggshell Membrane (NEM®) is an effective and safe
option for the treatment of pain and stiffness associated with
knee osteoarthritis. Supplementation with NEM®, 500 mg
taken once daily, significantly reduced both joint pain
and stiffness compared to placebo at 10, 30, and 60 days.
The Clinical Trial Registration number for this study is
NCT00750477.
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Introduction
Osteoarthritis (OA) is the most prevalent form of arthritis
and is estimated to affect nearly 27 million adults in the U.S.,
with one-third of those 65 and older having been diagnosed
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e-mail: ritz@drexel.eduwith OA [1]. As the population ages, this estimate is
expected to grow rapidly. Traditional treatments for OA
usually involve the use of analgesics (i.e., acetaminophen,
tramadol), non-steroidal anti-inflammatory drugs (NSAIDs)
(i.e., ibuprofen, diclofenac), or cyclooxygenase-2-specific
(COX-2) NSAIDs (i.e., celecoxib) alone or in combination.
Steroid and hyaluronic acid injections have also been used
with some success. Many of these treatments have shown
limited effectiveness in randomized controlled clinical trials
(RCTs) [2–5]. To avoid the cardiac risks [6–9]a n d
gastrointestinal issues [10, 11] associated with traditional
OA treatments (particularly with long-term use), many
patients have turned to complementary and alternative
medicines (CAMs) such as dietary supplements.
Glucosamine and chondroitin, alone and in combination,
are widely marketed as dietary supplements to treat joint
pain due to OA. There have been two major human clinical
trials that have investigated the role of these two dietary
supplements in the treatment of OA symptoms. The
Glucosamine/chondroitin Arthritis Intervention Trial (GAIT),
a 1,583-patient, 6-month trial sponsored by the National
Institutes of Health (NIH), failed to show significant
improvement in the Western Ontario and McMasters Univer-
sities (WOMAC) Osteoarthritis Index in the overall patient
populationforglucosamine,chondroitin,or their combination
[12]. The Glucosamine Unum In Die (once-a-day) Efficacy
(GUIDE) trial, a 318-patient, 6-month European trial
sponsored by industry, showed a small, 5–6% improvement
in total WOMAC Index score over placebo for glucosamine
sulfate [13]. Because of their limited effectiveness, the
search for additional CAMs to treat OA continues.
In the U.S. alone, an estimated 600,000 tons of eggshells
are produced annually as a by-product of the poultry
industry [14]. Disposal of these eggshells creates an
environmental and financial burden and, therefore, alterna-
tive uses for these materials would be of obvious benefit.
Eggshell membranes are primarily composed of fibrous
proteins such as collagen type I [15]. However, eggshell
membranes have also been shown to contain glycosamino-
glycans (GAGs), such as dermatan sulfate and chondroitin
sulfate [16], hexosamines, such as glucosamine, as well as
hexoses and fucose [17]. More recently, significant amounts
of hyaluronic acid have been detected in eggshell mem-
brane [18]. Other components identified in eggshell
membrane include sialic acid [19], desmosine and isodes-
mosine [20], ovotransferrin [21], lysyl oxidase [22], and
lysozyme [23].
The discovery of eggshell membrane as a natural source
of combined glucosamine, chondroitin, and hyaluronic acid
has prompted the evaluation of this material as a potential
treatment for OA. ESM Technologies, LLC (Carthage, MO,
USA) has developed methods to efficiently and effectively
separate eggshell membrane from eggshells to create a
shell-free eggshell membrane. The isolated membrane is
then partially hydrolyzed using a proprietary process and
dry blended to produce 100% pure Natural Eggshell
Membrane (NEM®).
In preliminary open-label human clinical trials totaling
37 subjects with joint and connective tissue disorders, oral
supplementationwith500mgperdayofNEM®resultedinan
observed decrease in pain in 7–30 days (unpublished report).
Therefore, an 8-week randomized, multicenter, double-blind,
placebo-controlled supplementation trial was conducted to
evaluate the efficacy and safety of NEM® for the relief of the
pain and stiffness associated with moderate OA of the knee—
the Osteoarthritis Pain Treatment IncorpOrating NEM®
(OPTION) trial. The results are presented herein.
Patients and methods
Study design
The OPTION study was conducted according to a random-
ized, multicenter, double-blind, placebo-controlled design
and was conducted in three rheumatology clinics in
Missouri (USA) in accordance with the U.S. Food & Drug
Administration’s principles of Good Clinical Practice (Title
21, Code of Federal Regulations, Parts 50 & 56 and ICH
E6) and the Declaration of Helsinki. The study protocol
was approved by an independent regional institutional
review board and patients provided their written informed
consent to participate. Subjects were required to suspend all
current pain relief medications in order to participate in the
study. Eligible subjects were then centrally randomized
among all sites to receive either NEM® or placebo in the
order in which they were enrolled in the study using a
permuted-block randomization table consisting of four
subjects per block. Patients, clinical investigators, and the
study coordinator were all blinded to the treatment through
the completion of the study. Treatment consisted once daily
orally of either NEM® (Membrell, LLC, USA) or placebo
(excipients) provided in 500 mg vegetarian capsules that
were stored in closed containers at ambient temperature.
Clinic visits were scheduled for subjects at 10, 30, and
60 days following the onset of treatment. Treatment
compliance was checked at clinic visits by patient interview
and by counting the number of unused doses of the study
medications. Acetaminophen was allowed for pain relief
rescue, if necessary. Subjects recorded the time and amount
of acetaminophen taken in patient diaries.
Patients
All subjects 18 years of age or older with known symp-
tomatic osteoarthritis of the knee were considered for
908 Clin Rheumatol (2009) 28:907–914enrollment in the study. In order to be eligible, patients
must have been diagnosed with functional grades I–III of
osteoarthritis according to the modified criteria of the
American College of Rheumatology [24]. Subjects must
also have had persistent knee pain associated with
osteoarthritis with a baseline score of at least 30 mm on
the Patient’s Assessment of Arthritis Pain—Visual Analog
Scale. Subjects were required to suspend all current pain
relief medications. Subjects that were currently taking
analgesic medications were eligible to participate in the
study following a 14-day washout period for NSAIDs, a
7-day washout for narcotics, and a 90-day washout for
injected steroids. Subjects currently taking glucosamine,
chondroitin sulfate, or MSM were only eligible after a
3-month washout period. Patients were excluded if they
were currently receiving remission-inducing drugs such as
methotrexate or immunosuppressive medications or had
received them within the past 3 months. They were also
excluded if they had a confounding inflammatory disease or
condition (rheumatoid arthritis, gout, pseudo gout, Paget’s
disease, chronic pain syndrome, etc.) that would interfere
with assessment of pain associated with the index knee.
Other exclusionary criteria were: body weight 113.5 kg
(250 lbs) or greater, a known allergy to eggs or egg
products, or pregnant or breastfeeding women. Subjects
previously enrolled in a study to evaluate pain relief within
the past 6 months or currently involved in any other
research study involving an investigational product (drug,
device, or biologic) or a new application of an approved
product, within 30 days of screening, were also excluded
from participating in the trial.
Treatment response
The primary endpoint of the study was measurement of the
effectiveness of NEM® in relieving pain, stiffness, and
discomfort associated with moderate OA of the knee and to
compare its effectiveness to placebo. The primary treatment
response endpoints were the 10-, 30-, and 60-day clinic
assessments utilizing the Western Ontario and McMasters
Universities (WOMAC) Osteoarthritis Index—Visual Ana-
log Scale (100 mm) version (VA 3.1) [25]. This version of
the WOMAC questionnaire consists of five questions ad-
dressing the severity of joint pain, two questions addressing
joint stiffness, and 17 questions addressing limitations in
performing physical activities (function). Endpoints were
compared to pretreatment assessments and to placebo
controls. In 2004, the Outcome Measures in Rheumatology
Clinical Trials (OMERACT) and the Osteoarthritis Re-
search Society International (OARSI) published criteria for
a response to treatment for osteoarthritis [26]. A treatment
response was classified as an improvement in pain or
function of at least 50% and a decrease of at least 20 mm on
the visual-analog scale for pain or function (WOMAC
subscales). Alternatively, the occurrence of two of the
following criteria also was acceptable as a treatment
response: a decrease in pain of at least 20% and at least
10 mm on the visual-analog scale; an improvement in
function of at least 20% and a decrease of at least 10 mm on
the visual-analog scale; and an increase in the patient’s
global assessment score by at least 20% and at least 10 mm
on the visual-analog scale. Patient’s global assessment
scores were not collected using a visual-analog scale;
however, we only review the OMERACT–OARSI response
rate with respect to the primary criterion. Patient’s and
Physician’s Global Assessments of Arthritis were also col-
lected utilizing a 0–5-point Likert scale.
Adverse events
Secondary objectives of the study were to evaluate tol-
erability and any adverse reactions associated with supple-
mentation with NEM®. The subjects’ self-assessment
diaries were reviewed and any discomfort or other adverse
events were recorded and reported in accordance with
applicable FDA regulations. Adverse events and serious
adverse events were assessed by the clinical investigator at
each study visit and followed until resolution, as necessary.
Serious adverse events were required to be reported to
the clinical monitor immediately using MedWatch OMB
No. 0910-0291.
Statistical analysis
An absolute increase in the mean response rate of 35%
(treatment rate versus placebo rate) was considered a
clinically meaningful treatment effect. It was estimated that
a sample size of 75 patients would need to be enrolled to
provide the study with a statistical power of 85% to detect a
clinically meaningful difference between the treatment
group and the placebo group, assuming a rate of response
of 40% in the treatment group, a rate of response of 5% in
the placebo group, and a withdrawal rate of 20%. Pairwise
comparisons of the treatment group with the placebo group
were made with a two-sided independent group t test at
baseline to validate randomization. Within-group compari-
sons, using a two-sided independent group t test, were also
made between testing sites to rule out any site bias. In both
cases, statistical significance was accepted at an α value of
<0.05. Post-baseline statistical analyses were done utilizing
repeated measures univariate analysis of variance (RM-
ANOVA) on pooled population data. Statistical significance
was accepted at an α value of <0.05 for between-group
interactions. Analysis of the primary outcome measure (the
difference between groups and the change from baseline in
overall WOMAC composite score as well as pain, stiffness,
Clin Rheumatol (2009) 28:907–914 909and function subscores) was conducted in the intent-to-treat
(ITT) population(i.e.,includingallrandomizedpatientswith
at least one efficacy assessment after randomization). The
last observation carried forward (LOCF) approach was used
for patients who made at least one follow-up visit but who
didnotcompletethestudy(losttofollow-up).Aper-protocol
completer analysis was also performed. SYSTAT software
(version 12) was used for all statistical analyses [27].
Results
Patient recruitment began in December 2004 at three
clinical sites in Missouri and the final follow-up was
conducted in January 2006. A total of 67 subjects were
enrolled in the trial and underwent randomization (see
Fig. 1). Of these subjects, 61.1% were from site 1, 29.9%
from site 2, and 9.0% from site 3. In terms of OA functional
grades, 20.9% were grade I, 28.4% were grade II, 20.9%
were grade III, and 29.9% were unassigned. Seven subjects
did not complete baseline evaluations, resulting in a total of
60 subjects in the intent-to-treat (ITT) population. Thirty-
one subjects (51.6%) were randomized to the placebo group
and 29 subjects (48.3%) were randomized to the NEM®
treatment group. Thirty-one percent (31%) of the ITT
subjects assigned to NEM® did not complete the 2-month
study per the protocol, compared with 42% of the ITT
subjects assigned to placebo. Of the 60 subjects in the ITT
population, six subjects assigned to placebo and two
subjects assigned to NEM® either violated the protocol or
did not begin treatment and, therefore, were not available
for further analysis. Those patients lost to follow-up before
the first evaluation time point in both the placebo (four
patients) and treatment (three patients) groups had symp-
tomatically mild OA (mean WOMAC 39.7 and 45.6,
respectively). Those patients lost to follow-up (primarily
withdrawals) in the remainder of the study in both the
placebo (three patients) and the treatment (four patients)
groups had symptomatically more severe OA (mean
WOMAC 76.6 and 63.7, respectively) compared to those
patients that completed the study (mean WOMAC at
baseline of 52.6 and 45.3, respectively). Five patients in
the placebo group and four patients in the treatment group
officially withdrew from the study due to lack of efficacy.
There were no obvious differences in the reason for
withdrawal between the study groups. The overall drop-
out rate of 43% (from enrollment) was considerably higher
than the estimated rate of 20%, although >70% of the
subjects that began treatment (n=54) completed the study
(excluding non-compliance). This is possibly related to the
small sample population or could also be due to the rela-
tively stringent pain management requirements of the study
protocol. Compliance with the study treatment regimen was
good in both treatment groups. In those subjects that com-
pleted the study, the rate of compliance was >97% (as judged
by capsule count at clinic visits).
Patient data was initially evaluated to ensure randomi-
zation within each site. Additionally, patient data was
67 Patients 
Randomized 
 
7 Patients did not 
complete baseline 
evaluation   
  
60 Patients 
ITT Population   
  
 
 
31 Assigned to 
Placebo   
29 Assigned to 
NEM
® 
4 Protocol Violations    
   (used prohibited pain  
   medication) 
5 Withdrew due to lack  
   of efficacy 
2 Lost to follow-up 
2 other reasons
 
 
2 Protocol Violations 
    (used prohibited pain  
    medication) 
4 Withdrew due to lack  
    of efficacy 
2 Lost to follow-up 
1 other reasons
  
 
 
18 Completed 
Study per Protocol
(58.1%) 
 
20 Completed 
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(69.0%) 
 
ITT = intent to treat; NEM  = Natural Eggshell Membrane
®
Fig. 1 Enrollment, randomiza-
tion, and completion flow
diagram
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of a characteristic placebo effect in the overall study
population, blinding was further scrutinized within the
placebo group. When evaluating the placebo group by site
and month enrolled, the placebo effect that was observable
was evenly distributed over time and between sites. That is,
there was a relevant placebo effect in six of the eight
months of enrollment across all sites. As there were no
observable systematic abnormalities in any of these
evaluations, the data were pooled for all subsequent
analyses. A clinical comparison of valid (excluding non-
compliance) subjects was carried out to obtain mean
baseline values (see Table 1). In all cases, the treatment
group values were slightly lower than those of the control
group, but were not statistically different. Analysis of the
primary outcome measure revealed that supplementation
with NEM® produced an absolute rate of response that was
significantly better (ranging from 10.3% to 26.6% improve-
ment) than placebo at all time points for both pain and
stiffness, but fell short of significance for function and
overall WOMAC, despite improving by 8.8% to 15.5% (see
Table 2). There were rapid responses seen for mean pain
subscores (15.9% reduction, P=0.036) and mean stiffness
subscores (12.8% reduction, P=0.024) occurring after only
10 days of supplementation. At 60 days, pain response was
maintained (15.4%, P=0.038), while stiffness had im-
proved further to 26.6% reduction (P=0.005). Mean
function subscores showed a 15.5% (P=0.084) absolute
improvement versus placebo at 10 days, which fell slightly
to 13.5% (P=0.076) by day 60. Overall mean WOMAC
Days post-treatment Treatment P value
Placebo NEM
Pain Baseline (n=25, 25) 50.6±19.4 44.0±16.8 0.204
10 (n=21, 24) 52.7±24.1 39.0±19.4 0.036*
30 (n=21, 24) 53.7±21.0 42.3±26.2 0.040*
60 (n=21, 24) 50.7±22.2 37.5±25.2 0.038*
Stiffness Baseline (n=25, 25) 59.3±24.0 50.5±20.3 0.167
10 (n=21, 24) 57.0±25.6 42.5±25.0 0.024*
30 (n=21, 24) 60.6±23.0 43.5±23.5 0.009*
60 (n=21, 24) 56.5±24.3 35.0±25.8 0.005*
Function Baseline (n=25, 25) 55.2±21.3 48.1±19.5 0.227
10 (n=21, 24) 57.3±24.6 43.3±23.0 0.084
30 (n=21, 24) 55.6±21.8 45.1±25.5 0.079
60 (n=21, 24) 53.1±24.9 40.5±27.1 0.076
Overall Baseline (n=25, 25) 54.6±20.4 47.5±17.5 0.191
10 (n=21, 24) 56.2±24.1 42.3±21.6 0.059
30 (n=21, 24) 55.5±21.4 44.4±25.1 0.055
60 (n=21, 24) 52.9±23.9 39.4±26.1 0.052
Table 1 Mean WOMAC scores
by category in NEM-
supplemented and control
groups at baseline and 10, 30,
and 60 days post-treatment
Values represent means±standard
deviations. P values were deter-
mined by repeated measures
univariate analysis of variance
(RM-ANOVA), and represent
treatment versus placebo
*P<0.05
Days post-treatment Placebo NEM Absolute treatment effect
Pain 10 (n=21, 24) +4.2% −11.7% −15.9%
30 (n=21, 24) +6.0% −4.3% −10.3%
60 (n=21, 24) +0.1% −15.3% −15.4%
Stiffness 10 (n=21, 24) −3.9% −16.7% −12.8%
30 (n=21, 24) +2.2% −14.6% −16.8%
60 (n=21, 24) −4.7% −31.3% −26.6%
Function 10 (n=21, 24) +3.9% −11.6% −15.5%
30 (n=21, 24) +0.8% −8.0% −8.8%
60 (n=21, 24) −3.8% −17.3% −13.5%
Overall 10 (n=21, 24) +2.9% −12.3% −15.2%
30 (n=21, 24) +1.7% −7.9% −9.6%
60 (n=21, 24) −3.1% −18.2% −15.1%
Table 2 Mean treatment effect
(%) in WOMAC scores from
baseline by category in NEM-
supplemented and control
groups at 10, 30, and 60 days
post-treatment
Values are mean treatment dif-
ferences calculated from Table 1
and are based upon the LOCF
approach. Negative values rep-
resent improvement or reduction
in symptom and positive values
represent the inverse
Clin Rheumatol (2009) 28:907–914 911scores resulted in a 15.2% (P=0.059) absolute improve-
ment versus placebo at 10 days, which was maintained at
60 days (15.1%, P=0.052). Thirty-two percent (32%) of
patients in the treatment group demonstrated a primary
OMERACT–OARSI response versus 12% of patients in the
placebo group by the end of the follow-up period (60 days,
P=0.023).
The study population was too small to stratify the
patients according to covariates, such as baseline pain level
or grade (I–III), to obtain statistically relevant data. There
was little difference between response rates for patients
with more severe OA (grades II/III) compared with patients
with less severe OA (grade I). About one-third of the
patients in both groups had at least a 40% reduction in pain
at 60 days.
Overall, the use of rescue pain medication was low
throughout the study, occurring once in every 6–8 days.
There were no significant differences among the groups for
rescue medication use. Approximately 17% of subjects took
acetaminophen significantly more often than average (once
every 3 days or less). After reviewing the patient diaries, it
was noted that many of the instances of acetaminophen use
were not for rescue purposes, but were actually for
headaches, backaches, and other issues unrelated to the
treatment knee. There were three adverse events reported
during the study and none of them were judged by clinical
investigators to be associated with treatment. There were no
serious adverse events reported during the study. Of
particular note is that there were no allergy-associated
adverse events during the study, although those with known
egg allergies were excluded from participating during
screening. In general, the treatment was reported to be
extremely well tolerated by study participants.
Discussion
Osteoarthritis is extremely prevalent and results in signifi-
cant costs, both financial and quality of life, for those that
suffer from the debilitating disease. The OPTION trial was
designed to evaluate the efficacy and safety of Natural
Eggshell Membrane as a treatment option for osteoarthritis.
Our preliminary study indeed proved NEM® both effective
and safe for treating pain and stiffness associated with OA
of the knee. NEM® has the added benefit of avoiding the
concerning side effects associated with long-term use of
other OA treatments such as NSAIDs.
Patients experienced a relatively rapid (10 days) re-
sponse for all WOMAC scores with a mean response of
approximately 15% (12.8% to 15.9%). By the end of the
follow-up period (60 days), the mean response remained
approximately 15% (13.5% to 15.4%) for all WOMAC
scores except stiffness which was 26.6%. While this is
superior to the response shown for glucosamine and
chondroitin in previous clinical investigations [12, 13], it
failed to reach the expected 35% response rate employed in
the clinical design. Despite this shortcoming, the results
were shown to be statistically significant. The safety profile
for NEM® is also of significance as there are no known
side effects, excluding the obvious egg allergy concern.
This is of obvious importance in a condition that requires
long-term treatment. Significant and sometimes serious side
effects associated with other OA treatments frequently
limits treatment options.
The measure of subjective symptoms (i.e., pain, stiff-
ness, etc.) of arthritis and the wide variation in individual
patient’s perception of these symptoms results in complex
relationships that can be difficult to elucidate from the
reporting of mean treatment effects in clinical trials and
may fail to adequately describe the potential benefits to the
individual patient [28–31].
Number Needed to Treat (NNT) is a form of responder
analysis and is a widely accepted and statistically valid
measure of treatment effect [32]. NNTs of 5 or below are
generally accepted as equating to an effective treatment for
pain-related conditions [30]. In order to perform an NNT
evaluation of the OPTION data, a treatment response rate
table was prepared for the treatment and placebo groups at
all time points for the pain (see Table 3) and stiffness (not
shown) WOMAC subscales. It becomes evident that there
are response rates that are quite likely to be clinically
relevant (i.e., ≥30% reduction from baseline). For example,
approximately one-third (33%) of study subjects experi-
enced greater than 30% reduction in pain at 10 days, with a
similar number of subjects (32%) having experienced
greater than 50% reduction in pain at 60 days. In both
% Reduction 10days 30days 60days
Placebo Treatment Placebo Treatment Placebo Treatment
n=21 n=24 n=20 n=22 n=18 n=19
≥20 24% 54% 35% 32% 39% 67%
≥30 14% 33% 20% 23% 33% 42%
≥40 10% 17% 10% 23% 22% 42%
≥50 5% 8% 5% 23% 12% 32%
Table 3 Percent of patients
experiencing reduction in pain
from Baseline at 10, 30, and
60 days post-treatment
912 Clin Rheumatol (2009) 28:907–914instances, this rate was more than two times (∼2.5×) that of
the placebo group. Approximately one-quarter (25%) of
study subjects experienced greater than 50% reduction in
stiffness at 10 days, with the number of patients increasing
to more than one-half (53%) having experienced this level
of improvement at 60 days. The 10-day result was more
than two times (∼2.5×) that of the placebo group and the
60-day result was nearly five times (∼4.8×) that of placebo.
These various responder rates were then converted to
NNT values which include 95% confidence intervals (95%
CI) according to the method described by Wen et al. [33].
NNT values were determined for each level of improve-
ment (as shown in Table 3) for both pain and stiffness. At
10, 30, and 60 days, NNTs for at least 50% reduction in
pain were 28.0 (95% CI, 26.2 to 29.8), 5.6 (3.9 to 7.4), and
5.0 (3.1 to 6.9), respectively. In clinical practice, one out of
every five patients should experience at least a 50%
reduction in pain within 30–60 days. By comparison, we
determined an NNT of 23.8 (95% CI, 15.2 to 32.4) from the
GAIT data for a 50% reduction in WOMAC pain scores for
the overall study population [12]. A similar 50% reduction
in rheumatoid arthritis pain was reported as 4 in a review of
three clinical trials for adalimumab, etenercept, and double-
dose infliximab [34].
NNT values were also determined for 50% reduction in
stiffness at each time point. We obtained NNTs of 6.5 (95%
CI, 4.6 to 8.4), 7.9 (6.1 to 9.7), and 2.4 (0.5 to 4.3) at 10,
30, and 60 days, respectively. This demonstrates that there
is a clinically relevant reduction in stiffness at all time
points during the study. This is particularly true at 60 days
where nearly one out of every two patients would
experience a 50% reduction in stiffness.
With one-third of those 65 and older having been
diagnosed with osteoarthritis [1], and that number expected
to grow immensely as the overall US population ages, it is
important for patients to have treatment options that are
both effective and safe. The reporting of the results from
the OPTION trial provides this needed treatment option.
The trial suffered from a number of issues. The limited
initial enrollment (67 subjects), the relatively high drop-out
rate (43%), and the smaller mean treatment effect than
anticipated (15% versus 35%) could have compromised the
statistical significance of the trial results. In addition to
these inherent limitations, combined they also prevented
post hoc analysis of subgroups of patients, say by severity
of disease. Less stringent requirements for concomitant pain
treatment or a more liberal rescue pain policy may have
reduced the drop-out rate considerably. The inclusion of a
comparative treatment agent may have provided additional
information, but would have required a significantly larger
study population. A larger follow-up study with some
modifications may allow us to better determine which
patients are most helped by NEM® supplementation.
Funding This study was supported by ESM Technologies, LLC.
Disclosures KJR is currently employed by the sponsor of the study.
AW and RWJ have no competing interests. DPD and BWR have
served as paid consultants for the sponsor of the study.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Lawrence RC, Felson DT, Helmick CG et al (2008) Estimates of
the prevalence of arthritis and other rheumatic conditions in the
United States. Part II. Arthritis Rheum 58(1):26–35
2. Case JP, Baliunas AJ, Block JA (2003) Lack of efficacy of
acetaminophen in treating symptomatic knee osteoarthritis. Arch
Intern Med 163:169–178
3. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC,
Wells G (2006) Acetaminophen for osteoarthritis. Cochrane
Database of Systematic Reviews, No. 2
4. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ (2002)
Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoar-
thritis of the knee. J Am Med Assoc 287(1):64–71
5. Altman RD (1999) Ibuprofen, acetaminophen and placebo in
osteoarthritis of the knee: a six-day double-blind study [abstract].
Arthritis Rheum 42:S403
6. Bresalier RS, Sandler RS, Quan H et al (2005) Cardiovascular
events associated with rofecoxib in a colorectal adenoma chemo-
prevention trial. N Engl J Med 352:1092–1102
7. Solomon SD, McMurray JJ, Pfeffer MA et al (2005) Cardiovas-
cular risk associated with celecoxib in a clinical trial for colorectal
adenoma prevention. N Engl J Med 352:1071–1080
8. Nussmeier NA, Whelton AA, Brown MT et al (2005) Complica-
tions of the COX-2 inhibitors parecoxib and valdecoxib after
cardiac surgery. N Engl J Med 352:1081–1091
9. Singh G, Wu O, Langhorne P, Madhok R (2006) Risk of acute
myocardial infarction with nonselective non-steroidal anti-
inflammatory drugs: a meta-analysis. Arthritis Res Ther 8(5):153–
162
10. Deeks JD, Smith LA, Bradley MD (2002) Efficacy, tolerability,
and upper gastrointestinal safety of celecoxib for treatment of
osteoarthritis and rheumatoid arthritis: systematic review of
randomised controlled trials. Br Med J 325:619–627
11. Laine L (1996) Nonsteroidal anti-inflammatory drug gastropathy.
Gastrointest Endosc Clin N Am 6(3):489–504
12. Clegg DO, Reda DJ, Harris CL et al (2006) Glucosamine,
chondroitin sulfate, and the two in combination for painful knee
osteoarthritis. N Engl J Med 354(8):795–808
13. Herrero-Beaumont G, Ivorra JAR, Trabado MC et al (2007)
Glucosamine sulfate in the treatment of knee osteoarthritis
symptoms. Arthritis Rheum 56(2):555–567
14. U.N. Food & Agriculture Organization: FAO Statistical Yearbook—
United States of America (2004)
15. Wong M, Hendrix MJC, von der Mark K et al (1984) Collagen in
the egg shell membranes of the hen. Devel Biol 104(1):28–36
16. Baker JR, Balch DA (1962) A study of the organic material of
hen's-egg shell. Biochem J 82:352–361
17. Picard J, Paul-Gardais A, Vedel M (1973) Sulfated glycoproteins
from egg shell membranes and hen oviduct. Isolation and
Clin Rheumatol (2009) 28:907–914 913characterization of sulfated glycopeptides. Biochimica et Biophy-
sica Acta 320:427–441
18. Long FD, Adams RG, and DeVore DP (September 20, 2005)
Preparation of hyaluronic acid from eggshell membrane. USA
Patent #6946551
19. Nakano T, Ikawa NI, Ozimek L (2003) Chemical composition of
chicken eggshell and shell membranes. Poult Sci 82:510–514
20. Starcher BC, King GS (1980) The presence of desmosine and
isodesmosine in eggshell membrane protein. Connect Tissue Res
8:53–55
21. Gautron J, Hincke MT, Panheleux M et al (2001) Ovotransferrin is
a matrix protein of the hen eggshell membranes and basal
calcified layer. Conn Tissue Res 42:255–267
22. Akagawa M, Wako Y, Suyama K (1999) The presence of
desmosine and isodesmosine in eggshell membrane protein.
Biochim Biophys Acta 14:151–160
23. Hincke MT, Gautron J, Panheleux M et al (2000) Identification
and localization of lysozyme as a component of eggshell
membranes and eggshell matrix. Matrix Biol 19:443–453
24. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe
F (1992) The American College of Rheumatology 1991 revised
criteria for the classification of global functional status in
rheumatoid arthritis. Arthritis Rheum 35:498–502
25. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW
(1988) Validation study of WOMAC: a health status instrument
for measuring clinically important patient relevant outcomes to
antirheumatic drug therapy in patients with osteoarthritis of the
hip or knee. J Rheumatol 15:1833–1840
26. Pham T, van der Heijde D, Altman RD et al (2004) OMERACT-
OARSI initiative: Osteoarthritis Research Society International set
of responder criteria for osteoarthritis clinical trials revisited.
Osteoarthritis Cartilage 12:389–399
27. Systat Software, Inc. , San Jose, CA, USA: www.systat.com
28. Tubach F, Ravaud P, Giraudeau B (2005) Managing osteoarthritis
of the knee: conclusions about use of NSAIDs are misleading. Br
Med J 330:672
29. McQuay H, Moore A (2007) Utility of clinical trial results for
clinical practice. Eur J Pain 11:123–124
30. Moore RA, Moore OA, Derry S, McQuay HJ (2008) Numbers
needed to treat calculated from responder rates give a better
indication of efficacy in osteoarthritis trials than mean pain scores.
Arthritis Res Ther 10(2):5
31. Lötsch J, Geisslinger G (2006) Current evidence for a genetic
modulation of the response to analgesics. Pain 121:1–5
32. Saver JL (2004) Number needed to treat estimates incorporating
effects over the entire range of clinical outcomes. Arch Neurol
61:1066–1071
33. Wen L, Badgett R, Cornell J (2005) Number needed to treat: a
descriptor for weighing therapeutic options. Am J Health Syst
Pharm 62(19):2031–2036
34. Kristensen LE, Christensen R, Bliddal H, Geborek P,
Danneskiold-Samsøe B, Saxne T (2007) The number needed to
treat for adalimumab, etanercept, and infliximab based on ACR50
response in three randomized controlled trials on established
rheumatoid arthritis: a systematic literature review. Scand J
Rheumatol 36:411–417
Key Messages
Natural Eggshell Membrane (NEM®), 500 mg taken once daily,
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